5 Best ETFs To Buy Now

In this article, we discuss 5 best ETFs to buy now. If you want to read our discussion on the stock market and ETF performance, head directly to 15 Best ETFs To Buy Now. 

5. Vanguard Russell 1000 Growth Index Fund ETF Shares (NASDAQ GS: VONG)

5-year Share Price Performance as of March 9, 2024: 121.02%

Vanguard Russell 1000 Growth Index Fund ETF Shares (NASDAQ GS: VONG) invests in stocks from the Russell 1000 Growth Index, a broadly diversified index primarily composed of growth stocks from large US companies. Launched on September 20, 2010, Vanguard Russell 1000 Growth Index Fund ETF Shares (NASDAQ GS: VONG) comes with an expense ratio of 0.08%, and holds a portfolio of 443 stocks. It is one of the best ETFs to invest in. 

Vanguard Russell 1000 Growth Index Fund ETF Shares (NASDAQ GS: VONG)’s top holdings include Eli Lilly and Company (NYSE:LLY). On December 8, Eli Lilly and Company (NYSE:LLY) declared a $1.30 per share quarterly dividend, a 15% increase from its prior dividend of $1.13. The dividend was paid on March 8. 

According to Insider Monkey’s fourth quarter database, 102 hedge funds were long Eli Lilly and Company (NYSE:LLY), same as the last quarter. Ken Fisher’s Fisher Asset Management is the leading stakeholder of the company, with 4.5 million shares worth $2.6 billion. 

Aristotle Atlantic Core Equity Strategy stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2023 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and neuroscience medicines. The company generates over half of its revenue in the U.S. from its top-selling drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment, Human pharmaceutical products.

Eli Lilly has a deep pipeline in treatment areas focused on metabolic disorders, oncology, immunology and central nervous system disorders. Currently, there are two phase three assets, Orforglipron, an oral GLP-1 and retatrutide, a triple incretin agonist, which have the potential to expand upon the potential success of Mounjaro. We believe that Mounjaro has the potential to commercialize beyond type 2 diabetes and obesity, potentially in the areas mentioned above of heart disease, sleep apnea, fatty liver disease and chronic kidney disease. We believe the premium valuation is supported by this outsized growth profile.”